Further investigation, including the urinary loss of these substances and metrics of inflammation in humans, is therefore warranted to elucidate the underlying mechanisms of the possible attenuated or diminished anemia-improving effect of SGLT2 inhibitors in patients with severely increased albuminuria. This evidence concerns the gene SLC5A2 and anemia (phenotype).